Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Rectal Neoplasms 8Stomach Neoplasms 5Nasopharyngeal Carcinoma 4Colorectal Neoplasms 4Breast Neoplasms 4Esophageal Neoplasms 3Neoplasm Metastasis 2Colonic Neoplasms 2Breast Cancer Metastatic 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Oesophagogastric Cancer 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Mid-low Rectal Cancer 1Metastatic Breast Cancer in the Brain 1Locally Advanced Rectal Cancer With Liver Metastases 1Locally Advanced Rectal Cancer 1Liver Metastases of Colorectal Cancer 1Immunotherapy 1HER2 Positive Metastatic Breast Cancer 1Colorectal Cancer Liver Metastasis 1Cholangiocarcinoma 1Advanced Breast Cancer 1

Interventions

tislelizumab 2Oxaliplatin 2apatinib 1Tegafur 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Immunotherapy × Capecitabine × Clear all
NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Not yet recruiting
94 enrolled

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡